BBI Solutions, an independent provider of immuno-diagnostic reagents and contract services, has acquired a German manufacturer.

BioTeZ Berlin-Buch, also including Steffens Biotechnische Analysen, is a manufacturer of reagents and finished tests for the in-vitro diagnostics market, as well as components for the food safety market.

Insider Media reports the deal aims to enhance BBI’s portfolio and position as a “complete” immunoassay reagent supplier.

BBI Group chief executive Mario Gualano said “This latest acquisition of BioTeZ and Steffens Biotec further enhances our portfolio and positions BBI as a leading immunoassay reagent supplier.

“It enables us to provide additional products and services in the fight against the Covid pandemic. The combined research and development capability will provide customers of both BioTeZ and BBI with new, innovative products and a broader portfolio for greater choice.

“BBI Solutions is a progressive company with ambitious strategies in place. This development is a great achievement, particularly in these unfamiliar and testing times.”

Uwe Ahnert, chief executive of BioTeZ, said “We are very proud to become part of the BBI family and to be able to reach many more customers worldwide.

“In doing so, we will be able to support them in the production and development of innovative diagnostics.”

WalesOnline reports the value of the deal has not been disclosed. Last June BBI itself was acquired by Danish investment firm Novo Holdings in a £400m deal.

BBI employs more than four hundred employees across its sites in seven countries and four continents. Its Crumlin HQ employs more than two hundred and fifty people. It also has UK sites in Kent, Salisbury and Edinburgh.